Abstract
Antiplatelet therapy plays a fundamental role in preventing thromboembolic events in patients with coronary artery disease (CAD). Clopidogrel is commonly used as an antiplatelet agent. Edoxaban, a direct-acting oral anticoagulant, has demonstrated efficacy in reducing thromboembolic events in various clinical contexts. However, it remains unclear whether the addition of edoxaban to clopid…